common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

A Study of Two Formulations of Ixekizumab in Healthy Participants

The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Ixekizumab

Administered SC.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects

common.study.values.clinical-trial-id

NCT04259346

participant.views.study.view.id

elYJJa